Literature DB >> 23329812

Genetic profiling identifies two classes of soft-tissue leiomyosarcomas with distinct clinical characteristics.

Antoine Italiano1, Pauline Lagarde, Céline Brulard, Philippe Terrier, Marick Laë, Bernard Marques, Dominique Ranchere-Vince, Jean-Jacques Michels, Martine Trassard, Angela Cioffi, Sophie Piperno-Neumann, Christine Chevreau, Jean-Yves Blay, Corinne Delcambre, Nicolas Isambert, Nicolas Penel, Jacques-Olivier Bay, Sylvie Bonvalot, Axel Le Cesne, Jean-Michel Coindre, Frédéric Chibon.   

Abstract

PURPOSE: Data about the prognostic factors of soft-tissue leiomyosarcomas and their correlation with molecular profile are limited. EXPERIMENTAL
DESIGN: From 1990 to 2010, 586 adult patients with a primary soft-tissue leiomyosarcoma were included in the French Sarcoma Group (GSF) database after surgery of the primary tumor. Multivariate analyses were conducted by Cox regression model in a backward stepwise procedure. Genetic profiling was conducted for 73 cases.
RESULTS: Median age was 59 years (range, 21-98 years). The median follow-up of patients alive was 46 months. The 5-year metastasis-free survival (MFS) rate was 51% (95% location and grade > I were independent adverse prognostic factors for MFS). The 5-year overall survival (OS) rate was 63% [95% confidence interval (CI), 59-67]. On multivariate analysis, age ≥ 60 years old, tumor size > 5 cm, deep location, and grade > I were independent adverse prognostic factors for OS. Molecular profiling identified specific clusters with activation of different biologic pathways: retroperitoneal leiomyosarcomas are characterized by overexpression of genes involved in muscle differentiation and nonretroperitoneal leiomyosarcomas characterized by overexpression of genes mainly involved in extracellular matrix, wounding, and adhesion pathways. The CINSARC signature but not comparative genomic hybridization (CGH) profiling was predictive of outcome.
CONCLUSION: Soft-tissue leiomyosarcomas represent a heterogeneous group of tumors with at least two categories, retroperitoneal and extremities leiomyosarcomas, having specific clinical outcome and molecular features. Future clinical trials should consider this heterogeneity for a better stratification of patients. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23329812     DOI: 10.1158/1078-0432.CCR-12-2970

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  18 in total

Review 1.  Role of genetic and molecular profiling in sarcomas.

Authors:  Scott M Norberg; Sujana Movva
Journal:  Curr Treat Options Oncol       Date:  2015-05

Review 2.  Physics of growing biological tissues: the complex cross-talk between cell activity, growth and resistance.

Authors:  Martine Ben Amar; Pierre Nassoy; Loic LeGoff
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2019-05-06       Impact factor: 4.226

Review 3.  Molecular profiling of sarcomas: new vistas for precision medicine.

Authors:  Tariq Al-Zaid; Wei-Lien Wang; Neeta Somaiah; Alexander J Lazar
Journal:  Virchows Arch       Date:  2017-06-29       Impact factor: 4.064

4.  Regulation of RNA polymerase III transcription during transformation of human IMR90 fibroblasts with defined genetic elements.

Authors:  Stéphanie Durrieu-Gaillard; Hélène Dumay-Odelot; Galina Boldina; Nicolas J Tourasse; Delphine Allard; Fabrice André; Françoise Macari; Armelle Choquet; Pauline Lagarde; Guillaume Drutel; Thierry Leste-Lasserre; Marion Petitet; Tom Lesluyes; Lydia Lartigue-Faustin; Jean-William Dupuy; Frédéric Chibon; Robert G Roeder; Dominique Joubert; Stéphan Vagner; Martin Teichmann
Journal:  Cell Cycle       Date:  2018-01-22       Impact factor: 4.534

5.  Clinically Relevant Molecular Subtypes in Leiomyosarcoma.

Authors:  Xiangqian Guo; Vickie Y Jo; Anne M Mills; Shirley X Zhu; Cheng-Han Lee; Inigo Espinosa; Marisa R Nucci; Sushama Varma; Erna Forgó; Trevor Hastie; Sharon Anderson; Kristen Ganjoo; Andrew H Beck; Robert B West; Christopher D Fletcher; Matt van de Rijn
Journal:  Clin Cancer Res       Date:  2015-04-20       Impact factor: 12.531

6.  Impact of preoperative treatment on the CINSARC prognostic signature: translational research results from a phase 1 trial of the German Interdisciplinary Sarcoma Group (GISG 03).

Authors:  Jens Jakob; Tom Lesluyes; Anna Simeonova-Chergou; Frederik Wenz; Peter Hohenberger; Frederic Chibon; Sophie Le Guellec
Journal:  Strahlenther Onkol       Date:  2019-11-15       Impact factor: 3.621

7.  Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.

Authors:  Inga-Marie Schaefer; Meijun Z Lundberg; Elizabeth G Demicco; Joanna Przybyl; Magdalena Matusiak; Frédéric Chibon; Davis R Ingram; Jason L Hornick; Wei-Lien Wang; Sebastian Bauer; Laurence H Baker; Alexander J Lazar; Matt van de Rijn; Adrian Mariño-Enríquez; Jonathan A Fletcher
Journal:  Cancer       Date:  2021-03-31       Impact factor: 6.860

Review 8.  Leiomyosarcoma: Does Location of Primary Help to Determine the Best Systemic Therapy Options?

Authors:  Jan Philipp Novotny; Suzanne George
Journal:  Curr Treat Options Oncol       Date:  2021-09-15

9.  Gene expression profiling in leiomyosarcomas and undifferentiated pleomorphic sarcomas: SRC as a new diagnostic marker.

Authors:  Rolando A R Villacis; Sara M Silveira; Mateus C Barros-Filho; Fabio A Marchi; Maria A C Domingues; Cristovam Scapulatempo-Neto; Samuel Aguiar; Ademar Lopes; Isabela W Cunha; Silvia R Rogatto
Journal:  PLoS One       Date:  2014-07-16       Impact factor: 3.240

Review 10.  Mesenchymal tumours of the gastrointestinal tract.

Authors:  Marta Sbaraglia; Gianluca Businello; Elena Bellan; Matteo Fassan; Angelo Paolo Dei Tos
Journal:  Pathologica       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.